US4386098A
Expired / Lapsed
US
⏱️ 0.0 years remaining
6-Hydroxy-2-benzothiazolesulfonamide for the topical treatment of elevated intraocular pressure
Assignee: Merck and Co Inc
•
Filing: 1981-11-03
•
Granted: 1983-05-31
•
Expires: 2001-11-03
Abstract
Abstract 6-Hydroxy-2-benzothiazolesulfonamide is useful for the topical treatment of elevated intraocular pressure. Ophthalmic compositions including drops and inserts are disclosed.
Inventors
- 👤 Otto Woltersdorf, Jr.
- 👤 Stuart R. Michelson
- 👤 John M. Sondey
- 👤 Harvey Schwam
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-26 08:53
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/33; A61K31/395; A61K31/41; A61K31/425; A61K9/00; A61K9/0012; A61K9/0048; A61P; A61P27/00; A61P27/02; A61P27/06; A61P43/00; C; C07; C07D; C07D277/00; C07D277/60; C07D277/62; C07D277/68; C07D277/70; C07D277/76; C07D277/80
Claims Analysis
Total Claims: 9
Claim 1
Independent Claim
36 words
A method for treating elevated intraocular pressure which comprises topically applying to an affected eye an intraocular pressure lowering effective amount of a carbonic anhydrase inhibitor of the formula: ##STR2## or an ophthalmologically acceptable salt thereof.
Claim 2
Independent Claim
36 words
A method for treating elevated intraocular pressure which comprises topically applying to an affected eye an intraocular pressure lowering effective amount of a carbonic anhydrase inhibitor of the formula: ##STR2## or an ophthalmologically acceptable salt thereof.
Claim 3
Dependent Claim
20 words
A method according to claim 1 wherein the carbonic anhydrase inhibitor is administered in a solid water soluble polymer insert.
Claim 4
Dependent Claim
19 words
A method according to claim 2 where said insert comprises from 0.01 to 35% by weight of said 6-hydroxy-2-benzothiazolesulfonamide.
Claim 5
Dependent Claim
11 words
A method according to claim 2 wherein the polymer is hydroxypropylcellulose.
Claim 6
Dependent Claim
15 words
A method according to claim 1 wherein the compound is administered in an ointment base.
Claim 7
Dependent Claim
26 words
A method according to claim 1 wherein said compound is administered as a 0.01 to 5% by weight preparation of the compound in a liquid vehicle.
Claim 8
Dependent Claim
39 words
An ophthalmic insert for the topical treatment of glaucoma and ocular hypertension comprising an intraocular pressure lowering effective amount of a compound having the formula: ##STR3## including pharmaceutically acceptable salts thereof and an ophthalmologically acceptable solid water soluble polymer.
Claim 9
Dependent Claim
39 words
An ophthalmic insert for the topical treatment of glaucoma and ocular hypertension comprising an intraocular pressure lowering effective amount of a compound having the formula: ##STR3## including pharmaceutically acceptable salts thereof and an ophthalmologically acceptable solid water soluble polymer.
References Cited (Backward Citations)
US3519630A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1986-05-30 | 1986-11-29 | 1987-05-31 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1990-05-30 | 1990-11-29 | 1991-05-31 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1994-05-30 | 1994-11-29 | 1995-05-31 | $7700.00 | Window Closed / Lapsed |